No Data
No Data
Buy Rating for Disc Medicine Driven by Promising Bitopertin Prospects and Strategic Advancements
Here's Why We're Not Too Worried About Disc Medicine's (NASDAQ:IRON) Cash Burn Situation
Promising Developments at Disc Medicine: NDA Filing and Phase III Trial for Bitopertin in EPP
LifeSci Capital Maintains Disc Medicine(IRON.US) With Buy Rating, Maintains Target Price $85
Disc Medicine's Strong Financial Health and Promising Clinical Pipeline Justify Buy Rating
Disc Medicine | 10-Q: Q1 2025 Earnings Report